Impact of Gender Affirming Hormone Therapy on Hematological Values of Transgender and Gender Diverse Patients: Research Article

Amy Wiser

doi:10.58372/2835-6276.1263

Authors

Amy Wiser

DOI:

https://doi.org/10.58372/2835-6276.1263

Keywords:

Transgender health, gender affirming care, hormonal replacement therapy, laboratory reference standards, complete blood count monitoring

Abstract

Purpose
It is recognized that sex hormones, including gender affirming hormone therapy (GAHT), affect the rate of erythropoiesis, demonstrated in complete blood count (CBC) measurements. While exogenous hormonal impact is understood, established reference ranges are based on sex assigned at birth, signifying endogenous hormone states. Leading organizations providing GAHT guidelines recommend using affirmed gender when assessing laboratory values. This study sought to further the understanding of the impact GAHT may have on hematological values through a statistical comparison of gendered adult laboratory values and population means.

Methods
A retrospective chart review of patients who received transgender healthcare at an urban university health system was performed. Electronic medical record documentation of transgender and gender diverse (TGD) patients on GAHT, meeting study criteria, allowed for categorical analysis of transmasculine and transfeminine cohort hematological laboratory values and comparison to adult cisgender laboratory derived population means.

Results
Criteria for analysis was met for 139 transmasculine and 57 transfeminine patients. Data identified statistically significant difference in transmasculine cohort red blood cell (RBC) means as well as hematocrit (Hct) means from those of both established cisgender male and cisgender female adult laboratory derived population mean values.

Conclusions
An advanced understanding of the impact of GAHT on common laboratory values is critical. Transmasculine RBC and Hct means existing between laboratory established adult cisgender male and cisgender female population means may impact the proper diagnosis and treatment of hematological based clinical conditions. Further research studies on hematological laboratory values of the TGD population may improve the equity and quality of care received.

References

Coleman E, Radix AE, Bouman WP, et al. WPATH: Standards of care for the health of transgender and gender diverse people, Version 8. Int J Transgend Health 2022;23(Suppl 1):S1-S259;doi: 10.1080/26895269.2022.2100644.

Thompson J, Hopwood RA, de Normand S, et al. Fenway Health. Medical care of trans and gender diverse adults. Boston, MA; 2021. Available from: https://fenwayhealth.org/wp-content/uploads/Medical-Care-of-Trans-and-Gender-Diverse-Adults-Spring-2021-1.pdf. [Last accessed: October 11, 2023].

Deutsch MB. UCSF Center for Transgender Excellence. Guidelines for the primary and gender-affirming care of transgender and gender nonbinary people. San Francisco, CA. 2016. Available from: https://transcare.ucsf.edu/guidelines [Last accessed: October 11, 2023].

Hembree WC, Cohen-Kettenis PT, Gooren L, et al. Endocrine treatment of gender-dysphoric/gender-incongruent persons: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2017;102(11):3869-3903;doi: 10.1210/jc.2017-01658. Erratum in: J Clin Endocrinol Metab 2018;103(2):699;doi: 10.1210/jc.2017-02548. Erratum in: J Clin Endocrinol Metab 2018;103(7):2758-2759;doi: 10.1210/jc.2018-01268.

U.S. Transgender Survey. Oregon State Report. National Center for Transgender Equality. Washington DC; 2017. Available from: http://www.transequality.org/sites/default/files/docs/usts/USTSORStateReport(1017).-pdf. [Last accessed: May 17, 2024].

Clark KD, Sherman ADF, Flentje A. Health insurance prevalence among gender minority people: a systematic review and meta-analysis. Transgend Health 2022;7(4):292-302;doi: 10.1089/trgh.2020.0182.

Macapagal K, Bhatia R, Greene GJ. Differences in healthcare access, use, and experiences within a community sample of racially diverse lesbian, gay, bisexual, transgender, and questioning emerging adults. LGBT Health 2016;3(6):434-442;doi: 10.1089/lgbt.2015.0124.

Gillani B, Prince DM, Ray-Novak M, et al. Mapping the dynamic complexity of sexual and gender minority healthcare disparities: a systems thinking approach. Healthcare (Basel) 2024;12(4):424;doi: 10.3390/healthcare12040424.

Englund HM. Minority stress and health disparities in lesbian, gay, bisexual, transgender, and queer or questioning adults. Nurs Clin North Am 2023;58(4):495-503;doi: 10.1016/j.cnur.2023.06.002.

Jones J. Social & Policy Issues. LGBTQ+ Identification in U.S. Now at 7.6%. Washington DC; 2024. Available from: http://news.gallup.com/poll/611864/lgbtq-identification.aspx. [Last accessed: May 17, 2024].

Wylie K, Knudson G, Khan SI, et al. Serving transgender people: clinical care considerations and service delivery models in transgender health. Lancet 2016;388(10042):401-411;doi: 10.1016/S0140-6736(16)00682-6.

Chen WJ, Radix AE. Primary care and health care of transgender and gender-diverse older adults. Clin Geriatr Med 2024;40(2):273-283;doi: 10.1016/j.cger.2023.12.003.

Klein DA, Paradise SL, Goodwin ET. Caring for transgender and gender-diverse persons: what clinicians should know. Am Fam Physician 2018;98(11):645-653.

Greene DN, McPherson GW, Rongitsch J, et al. Hematology reference intervals for transgender adults on stable hormone therapy. Clin Chim Acta 2019;492:84-90;doi: 10.1016/j.cca.2019.02.011.

Greene DN, Schmidt RL, Winston-McPherson G, et al. Reproductive endocrinology reference intervals for transgender men on stable hormone therapy. J Appl Lab Med 2021;6(1):41-50;doi: 10.1093/jalm/jfaa169.

Allen AN, Jiao R, Day P, et al. Dynamic impact of hormone therapy on laboratory values in transgender patients over time. J Appl Lab Med 2021;6(1):27-40;doi: 10.1093/jalm/jfaa192.

Ana Antun, Qi Zhang, Shalender Bhasin, et al. Longitudinal changes in hematologic parameters among transgender people receiving hormone therapy. J Endocr Soc 2020;4(11);doi: 10.1210/jendso/bvaa119.

Greene DN, Schmidt RL, Winston McPherson G, et al. Reproductive endocrinology reference intervals for transgender women on stable hormone therapy. J Appl Lab Med 2021;6(1):15-26;doi: 10.1093/jalm/jfaa028.

Stangl TA, Wiepjes CM, Defreyne J, et al. Is there a need for liver enzyme monitoring in people using gender-affirming hormone therapy? Eur J Endocrinol 2021;184(4):513-520;doi: 10.1530/EJE-20-1064.

Wierckx K, Van Caenegem E, Schreiner T, et al. Cross-sex hormone therapy in trans persons is safe and effective at short-time follow-up: results from the European network for the investigation of gender incongruence. J Sex Med 2014;11(8):1999-2011;doi: 10.1111/jsm.12571.

Ott J, Aust S, Promberger R, Huber JC, et al. Cross-sex hormone therapy alters the serum lipid profile: a retrospective cohort study in 169 transsexuals. J Sex Med 2011;8:2361-9;doi: 10.1111/j.1743-6109.2011.02311.x.

Roberts TK, Kraft CS, French D, et al. Interpreting laboratory results in transgender patients on hormone therapy. Am J Med 2013;127(2):159-62;doi:10.1016/j.amjmed.2013.10.009.

SoRelle JA, Jiao R, Gao E, et al. Impact of hormone therapy on laboratory values in transgender patients. Clin Chem 2019;65(1):170-79;doi:10.1373/clinchem.2018.292730.

Goldstein Z, Streed C, Resiman T, et al. Cross-sex hormones, and acute cardiovascular events in transgender persons. Ann Intern Med 2019;170(2):142;doi:10.7326/l18-0563.

Vita R, Settineri S, Liotta M, et al. Changes in hormonal and metabolic parameters in transgender subjects on cross-sex hormone therapy: a cohort study. Maturitas 2017;107:92-6; doi:10.1016/j.maturitas.2017.10.012.

Houghton DE, Alsawas M, Barrioneuvo P, et al. Testosterone therapy and venous thromboembolism: a systematic review and meta-analysis. Throm Res 2018;172: 94-103; doi:10.1016/j.thromres.2018.10.023.

Arnett D, Blumenthal R, Albert M, et al. 2019 ACC/AHA guideline on the primary prevention of cardiovascular disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. Circulation 2019;140:e596–e646;doi: 10.1161/CIR.0000000000000678.

Kandhro A. Hematological parameters in transgender persons. HTIJ 2016;2(4):79;doi: 10.15406/htij.2016.02.00044.

Elamin MB, Garcia MZ, Murad MH, et al. Effect of sex steroid use on cardiovascular risk in transsexual individuals: a systematic review and meta-analyses. Clin Endocrinol 2010;72(1):1-10;doi: 10.1111/j.1365-2265.2009.03632.x.

Reed AH, Henry RJ, Mason WB. Influence of statistical method used on the resulting estimate of normal range. Clin Chem 1971;17(4):275-84.

Velho I, Fighera TM., Ziegelmann PK, et al. Effects of testosterone therapy on BMI, blood pressure, and laboratory profile of transgender men: a systematic review. J. Androl 2017; 5(5):881-88;doi:10.1111/andr.12382.

Women's Reproductive Health. Reproductive Health. CDC, Centers for Disease Control and Prevention. Atlanta, GA; 2024 Available from: https://www.cdc.gov/reproductivehealth/womensrh/index.htm. [Last accessed: August 11, 2024].

Martinez GM, Daniels K. Fertility of men and women aged 15-49 in the United States; National Survey of Family Growth, 2015-2019. National Health Statistics Reports; no 179. Hyattsville, MD; Nation Center for Health Statistics; 2023. Available from: https://www.cdc.gov/nchs/data/nhsr/nhsr179.pdf. [Last accessed: August 11, 2024].

Streed CG, King D, Grasso C, et al. Validation of an administrative algorithm for transgender and gender diverse persons against self-report data in electronic health records. J Am Med Inform Assoc 2023;19;30(6):1047-55;doi: 10.1093/jamia/ocad039.

Tamí-Maury I, Sharma A, Chen M, et al. Comparing smoking behavior between female-to-male and male-to-female transgender adults. Tob Prev Cessat 2020;6:2;doi: 10.18332/tpc/114513.

Centers for Disease Control and Prevention. Tips from former smokers. LGBTQ+ people. Atlanta, GA; 2021. Available from: https://www.cdc.gov/tobacco/campaign/tips/groups/lgbt.html [Last accessed: November 2, 2023].

Centers for Disease Control and Prevention. National Center for Health Statistics. Tobacco use. Atlanta, GA; 2021. Available from: https://www.cdc.gov/nchs/hus/topics/tobacco-use.html [Last accessed: November 2, 2023].

Pedersen KM, Çolak Y, Ellervik C, et al. Smoking and increased white and red blood cells. Arterioscler. Thromb. Vasc. Biol. 2019;39(5):965-77;doi: 10.1161/ATVBAHA.118.312338.

Eisenga MF, Kieneker LM, Touw DJ, et al. Active smoking and hematocrit and fasting circulating erythropoietin concentrations in the general population. Mayo Clin. Proc. 2018;93(3):337-43;doi: 10.1016/j.mayocp.2018.01.005.

Herman JL, Flores AR, O’Neill KK. UCLA School of Law. Williams Institute. How Many Adults and Youth Identify as Transgender in the United States? Los Angeles, CA; 2022. Available from: http://williamsinstitute.law.ucla.edu/publications/trans-adults-united-states/. [Last accessed: May 17, 2024].

Hines NG, Greene DN, Imborek KL, et al. Patterns of gender identity data within electronic health record databases can be used as a tool for identifying and estimating the prevalence of gender-expansive people. JAMIA Open 2023; 6(2):ooad042;doi: 10.1093/jamiaopen.ooad042.